Paper - WANFANG MED ONLINE

You Position: Home > Paper

Advance of several types of important marine antitumor drugs

( views:343, downloads:49 )

Author:: No author available

Journal Title:: ACTA PHARMACEUTICA SINICA

Issue:: 5

DOI:: 10.3321/j.issn:0513-4870.2008.05.001

Key Word:: 海洋天然产物;抗肿瘤药物;研究进展

Abstract：目前对海洋抗肿瘤药物的研究已经成为全世界普遍关注的热点.近年来,苔藓抑素、ecteinascidin-743、海兔毒肽、膜海鞘素、psammaplin、软海绵素B等六类化合物的研究取得了较大进展.本文综述这几类海洋抗肿瘤药物及其衍生物的研究进展.并探讨海洋抗肿瘤药物发展的趋势.

Reference

[1]Kortmansky J,Schwartz GK.Bryostatin-1: a novel PKC inhibitor in clinical development.[J].2003,21(6).
[2]Alkon DL,Sun MK.Dual effects of bryostatin-1 on spatial memory and depression.[J].2005,512(1).
[3]Dabydeen DA,Burnett JC,Bai R,etc.Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.[J].2006,70(6).
[4]Misset JL,Taamma A,Spielmann M,etc.A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.[J].2006,94(11).
[5]Mark A, Hoffman,John A, Blessing,Samuel S, Lentz.A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.[J].2003,89(1).
[6]Wall NR,Mohammad RM,Al-Katib AM.Mitogen-activated protein kinase is required for bryostatin 1-induced differentiation of the human acute lymphoblastic leukemia cell line Reh.[J].2001,12(12).
[7]John L, Marshall,Neelesh, Bangalore,Dorraya, El-Ashry,etc.Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies.[J].1900,1.
[8]Zhi-Gang She,Xue-Kui Xia,Hua-Rong Huang.Structural and Biological Properties of Vermistatin and Two New Vermistatin Derivatives Isolated from the Marine-Mangrove Endophytic Fungus Guignardia sp. No. 4382[J].2007,90(10).
[9]Manzanares I.,Cuevas C.,Gago F.,etc.A 3 center dot(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions[J].2002,45(4).
[10]Cragg GM,Newman DJ.Marine natural products and related compounds in clinical and advanced preclinical trials.[J].2004,67(8).
[11]Sredni B,Gafter U,Longo DL,etc.Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model.[J].2007,21(7).
[12]Jian-ye, Zhang,Hai-ying, Wu,Xue-kui, Xia,etc.Anthracenedione derivative 1403P-3 induces apoptosis in KB and KBv200 cells via reactive oxygen species-independent mitochondrial pathway and death receptor pathway.[J].2007,6(9).
[13]Chang BB,Cherny RC,Ajani JA,etc.A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma.[J].2006,24(4).
[14]Decouvelaere AV,Coquard IR,Fayette J,etc.ET-743: a novel agent with activity in soft-tissue sarcomas.[J].2006,18(4).
[15]Goel R,Soulieres D,Jimeno J,etc.Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.[J].2006,17(9).
[16]R L, Bai,K D, Paull,C L, Herald,etc.Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.[J].1991,266.
[17]Pestka S,Garcia CS,Curiel RE,etc.The antineoplastic agent Bryostatin-1 differentially regulates IFN-gamma receptor subunits in monocytic cells: transcriptional and posttranscriptional control of IFN-gammaR2.[J].2006,177(4).
[18]H L SingsK L Rinehart.Compounds produced from potential tunicate-blue-green algal symbiosis: A review[J].1996,17(5-6).
[19]Turner ML,Roddie PH,Horton Y.Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1.[J].2002,16(1).
[20]Borsotti P,Sironi M,Jimeno J,etc.Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.[J].2003,17(1).
[21]Wang Z,Dai Y,Wang S,etc.Bryostatin 1 increases 1-beta-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L).[J].2002,301(2).
[22]Kim IW,Chen ZS,Shi Z,etc.Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.[J].2007,98(9).
[23]Fayette J,Coquard IR,Blay JY,etc.ET-743: a novel agent with activity in soft tissue sarcomas.[J].2005,10(10).
[24]Zobeida, Cruz-Monserrate,Jeffrey T, Mullaney,Patrick G, Harran,etc.Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.[J].2003,270(18).
[25]Jimeno J,Faircloth GT,Tognon G,etc.Effect of Aplidin in acute lymphoblastic leukaemia cells.[J].2003,89(4).
[26]Tercero JC,Blanco-Aparicio C,Jimeno J,etc.Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.[J].2007,100(2).
[27]Kobayashi M,Natsume T,Fujio N,etc.Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo.[J].2003,94(9).
[28]Remiszewski SW.The discovery of NVP-LAQ824: from concept to clinic.[J].2003,10(22).
[29]Sun MK,Alkon DL.Bryostatin-1: pharmacology and therapeutic potential as a CNS drug.[J].2006,12(1).